Bioage Labs (NASDAQ: BIOA) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 44.44 percent decrease over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $2.772 million which beat the analyst consensus estimate of $1.083 million by 155.88 percent. This is a 91.04 percent increase over sales of $1.451 million the same period last year.